Management of Extensive Dermatophytosis: A Comprehensive Review
Keywords:
N\AAbstract
Dermatophytosis is a superficial fungal infection of the skin caused by keratinophilic fungi. Based on the extent of body surface area involved, it can be classified as mild, moderate and severe (extensive) infection. Topical antifungals can be used for treating mild to moderate infections whereas, for extensive involvement, systemic antifungal therapy is the mainstay of treatment. The most commonly used oral antifungals for treating dermatophytosis are fluconazole, terbinafine, itraconazole, griseofulvin, ketoconazole and rarely amphotericin-B, voriconazole and posaconazole. Presently, there is an adequate armamentarium of oral antifungal drugs but despite this, there is a rising trend of recalcitrant and recurrent dermatophyte infections. The reasons for this could be the emergence of resistance to the currently used antifungals, poor compliance of the patient to the treatment owing to the exorbitant cost of the newer oral antifungal drugs.
Downloads
References
Sahoo A, Mahajan R. Management of tinea corporis, tinea cruris, and tinea pedis: A comprehensive review. Indian Dermatol Online J. 2016;7(2):77–86.
Sudha M, Ramani C, Anandan H. Prevalence of dermatophytosis in patients in a tertiary care centre. International Journal of Contemporary Medical Research. 2016;3(8):2399–401.
Hay RJ, Ashbee RH. Fungal infections. In: Griffiths C, Barker J, Bleiker T, Chalmers R, Creamer D, editors. Fungal infections. Ninth edition. Chichester, West Sussex; Hoboken, NJ: John Wiley & Sons Inc; 2016. p. 32.1-70.
Degreef H. Clinical forms of dermatophytosis (ringworm infection). Mycopathologia. 2008;166(5):257–65.
Rajagopalan M, Inamadar A, Mittal A, Miskeen AK, Srinivas CR, Sardana K, et al. Expert consensus on the management of dermatophytosis in India (ECTODERM India). BMC Dermatol. 2018;18(1):6.
Robert R, Pihet M. Conventional methods for the diagnosis of dermatophytosis. Mycopathologia. 2008;166(5):295–306.
Ghannoum M, Salem I, Christensen L. Antifungals. In: Kang S, editor. Fitzpatrick’s dermatology. Ninth edition. New York: McGraw-Hill Education; 2019. p. 3436–50.
Lewis RE. Current concepts in antifungal pharmacology. Mayo Clin Proc. 2011;86(8):805–17.
Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. Mycopathologia. 2008;166(5):353–67.
Zhang AY, Camp WL, Elewski BE. Advances in topical and systemic antifungals. Dermatol Clin. 2007;25(2):165–83.
Del Palacio Hernandez A, López Gómez S, González Lastra F, Moreno Palancar P, Iglesias Díez L. A comparative double-blind study of terbinafine (Lamisil) and griseofulvin in tinea corporis and tinea cruris. Clin Exp Dermatol. 1990;15(3):210–6.
Brodell RT, Elewski B. Antifungal drug interactions. Avoidance requires more than memorization. Postgrad Med. 2000;107(1):41–3.
Pilmis B, Jullien V, Sobel J, Lecuit M, Lortholary O, Charlier C. Antifungal drugs during pregnancy: An updated review. J Antimicrob Chemother. 2015;70(1):14–22.
Stone NRH, Bicanic T, Salim R, Hope W. Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions. Drugs. 2016;76(4):485–500.
Sinha S, Sardana K. Antifungal Efficacy of Amphotericin B against Dermatophytes and its Relevance in Recalcitrant Dermatophytoses: A Commentary. Indian Dermatol Online J. 2018;9(2):120–2.
Ryder NS. Terbinafine: mode of action and properties of the squalene epoxidase inhibition. Br J Dermatol. 1992;126(Suppl 39):2–7.
Dias MFRG, Bernardes-Filho F, Quaresma-Santos MVP, Amorim AG da F, Schechtman RC, Azulay DR. Treatment of superficial mycoses: review - part II. An Bras Dermatol. 2013;88(6):937–44.
Leyden J. Pharmacokinetics and pharmacology of terbinafine and itraconazole. J Am Acad Dermatol. 1998;38(5):42–7.
Abdel-Rahman S, Newland. Update on terbinafine with a focus on dermatophytoses. Clin Cosmet Investig Dermatol. 2009;2:49–63.
Dismukes WE. Antifungal Therapy: Lessons learned over the past 27 Years. Clin Infect Dis. 2006;42(9):1289–96.
Mast N, Zheng W, Stout CD, Pikuleva IA. Antifungal Azoles: Structural insights into undesired tight binding to cholesterol-metabolizing CYP46A1. Mol Pharmacol. 2013;84(1):86–94.
Lewis JH, Zimmerman HJ, Benson GD, Ishak KG. Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. Gastroenterology. 1984;86(3):503–13.
Cauwenbergh G, Degreef H, Heykants J, Woestenborghs R, Van Rooy P, Haeverans K. Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol. 1988;18(2):263–8.
Ashley ESD, Lewis R, Lewis JS, Martin C, Andes D. Pharmacology of systemic antifungal agents. Clin Infect Dis. 2006;43(Suppl 1):28–39.
Donnelly JP, De Pauw BE. Voriconazole—a new therapeutic agent with an extended spectrum of antifungal activity. Clin Microbiol Infect. 2004;10(Suppl 1):107–17.
Ghannoum M, Isham N, Sheehan D. Voriconazole susceptibilities of dermatophyte isolates obtained from a worldwide tinea capitis clinical Trial. J Clin Microbiol. 2006;44(7):2579–80.
Nagappan V, Deresinski S. Posaconazole: A Broad-Spectrum Triazole Antifungal Agent. Clin Infect Dis. 2007;45(12):1610–7.
Pasqualotto AC, Thiele KO, Goldani LZ. Novel triazole antifungal drugs: Focus on isavuconazole, ravuconazole and albaconazole. Curr Opin Invest Dr. 2010;11(2):165–74.
Srinivasan A, Lopez-Ribot JL, Ramasubramanian AK. Overcoming antifungal resistance. Drug Discov Today Technol. 2014;11:65–71.
Schaller M, Friedrich M, Papini M, Pujol RM, Veraldi S. Topical antifungal-corticosteroid combination therapy for the treatment of superficial mycoses: conclusions of an expert panel meeting. Mycoses. 2016;59(6):365–73.
Kanafani ZA, Perfect JR. Resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis. 2008;46(1):120–8.
White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev. 1998;11(2):382–402.
Osborne CS, Leitner I, Favre B, Ryder NS. Amino acid substitution in Trichophyton rubrum squalene epoxidase associated with resistance to terbinafine. Antimicrob Agents Chemother. 2005;49(7):2840–4.
Osborne CS, Leitner I, Hofbauer B, Fielding CA, Favre B, Ryder NS. Biological, biochemical, and molecular characterization of a new clinical Trichophyton rubrum isolate resistant to terbinafine. Antimicrob Agents Chemother. 2006;50(6):2234–6.
Fachin AL. Role of the ABC transporter TruMDR2 in terbinafine, 4-nitroquinoline N-oxide and ethidium bromide susceptibility in Trichophyton rubrum. J Med Microbiol. 2006;55(8):1093–9.
Peres NT, Sanches PR, Falcão JP, Silveira HC, Paião FG, Maranhão FC, et al. Transcriptional profiling reveals the expression of novel genes in response to various stimuli in the human dermatophyte Trichophyton rubrum. BMC Microbiol. 2010;10(1):39.
Yu L, Zhang W, Wang L, Yang J, Liu T, Peng J, et al. Transcriptional profiles of the response to ketoconazole and amphotericin B in Trichophyton rubrum. Antimicrob Agents Chemother. 2007;51(1):144–53.
Singh A, Masih A, Khurana A, Singh PK, Gupta M, Hagen F, et al. High terbinafine resistance in Trichophyton interdigitale isolates in Delhi, India harbouring mutations in the squalene epoxidase gene. Mycoses. 2018;61(7):477–84.
Rudramurthy SM, Shankarnarayan SA, Dogra S, Shaw D, Mushtaq K, Paul RA, et al. Mutation in the squalene epoxidase gene of Trichophyton interdigitale and Trichophyton rubrum associated with allylamine resistance. Antimicrob Agents Chemother. 2018;62(5):1–10.
Degreef HJ. Current therapy of dermatophytosis. J Am Acad Dermatol. 1994;31(3):25–30.
Cáceres-Ríos H, Rueda M, Ballona R, Bustamante B. Comparison of terbinafine and griseofulvin in the treatment of tinea capitis. J Am Acad Dermatol. 2000;42(1):80–4.
Mukherjee PK, Leidich SD, Isham N, Leitner I, Ryder NS, Ghannoum MA. Clinical Trichophyton rubrum strain exhibiting primary resistance to terbinafine. Antimicrob Agents Chemother. 2003;47(1):82–6.
Hryncewicz-Gwóźdź A, Kalinowska K, Plomer-Niezgoda E, Bielecki J, Jagielski T. Increase in resistance to fluconazole and itraconazole in Trichophyton rubrum clinical isolates by sequential passages in vitro under drug Pressure. Mycopathologia. 2013;176(1–2):49–55.
Ghannoum M. Azole resistance in dermatophytes: Prevalence and mechanism of action. J Am Podiatr Med Assoc. 2016;106(1):79–86.
Azambuja CV de A, Pimmel LA, Klafke GB, Xavier MO. Onychomycosis: clinical, mycological and in vitro susceptibility testing of isolates of Trichophyton rubrum. An Bras Dermatol. 2014;89(4):581–6.
Verma S, Madhu R. The great Indian epidemic of superficial dermatophytosis: An appraisal. Indian J Dermatol. 2017;62(3):227–36.
Ghannoum MA, Arthington-Skaggs B, Chaturvedi V, Espinel-Ingroff A, Pfaller MA, Rennie R, et al. Interlaboratory study of quality control isolates for a broth microdilution method (Modified CLSI M38-A) for testing susceptibilities of dermatophytes to antifungals. J Clin Microbiol. 2006;44(12):4353–6.
Verma SB. Complex cost issues in treating dermatophytoses in India-"It all builds up". Indian Dermatol Online J. 2019;10(4):441–3.
Nirmala S, Shanker B, Sentamilselvi G, Janki C. Efficacy and safety of systemic antifungal agents in chronic dermatophytosis -An open trial. Indian J Dermatol. 2000;45(1):14–6.
Das N, Sil A, Tripathi S, Ghosh P, Das P, Islam C. A study to evaluate the price control of antifungal medicines and its practical applicability. Indian J Pharmacol. 2012;44(6):704–9.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
